Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
QuintilesIMS
Dow
Cipla
Argus Health
Chubb
McKesson
Healthtrust
Teva

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,327,844

« Back to Dashboard

Summary for Patent: 8,327,844
Title:Nasal delivery method
Abstract: A delivery device (20, 22) for and a method of delivering a substance to the nasal airway (1) of a subject, in particular the posterior region of the nasal airway, the delivery device comprising: a closure unit for causing the closure of the oropharyngeal velum of the subject; and a delivery unit for delivering a gas flow entraining a substance to one of the nostrils of the subject at such a driving pressure as to flow around the posterior margin of the nasal septum and out of the other nostril of the subject, wherein the delivery unit comprises a nosepiece (30, 40, 58, 82, 102, 132) which includes an outlet through which the gas flow is in use delivered to the one nostril and a sealing member for sealing the one nostril to the outlet such as in use to prevent the escape of the gas flow through the one nostril.
Inventor(s): Djupesland; Per Gisle (Oslo, NO)
Assignee: OptiNose AS (Oslo, NO)
Application Number:10/813,326
Patent Claim Types:
see list of patent claims
Use; Delivery; Device; Formulation;

Drugs Protected by US Patent 8,327,844

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Avanir Pharms ONZETRA XSAIL sumatriptan succinate POWDER;INHALATION 206099-001 Jan 27, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY ➤ Sign Up
Optinose Us Inc XHANCE fluticasone propionate SPRAY, METERED;NASAL 209022-001 Sep 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,327,844

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9904906.6Mar 3, 1999
United Kingdom9911686.5May 19, 1999

Non-Orange Book US Patents Family Members for Patent 8,327,844

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,555,877 Nasal delivery device ➤ Sign Up
8,511,303 Nasal delivery devices ➤ Sign Up
7,543,581 Nasal devices ➤ Sign Up
9,468,727 Nasal delivery ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Dow
US Army
US Department of Justice
Fish and Richardson
Queensland Health
Cipla
Chubb
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.